GMT Share Price Performance
zł6.38
-1.10 (-14.71%)
Price zł6.38
Share Pricezł6.38
Genomtec S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
GMT Community Narratives
There are no narratives available yet.
Recent GMT News & Updates
Genomtec S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.78
- Gross Margin
- -62,581.82%
- Net Profit Margin
- -106,572.73%
- Debt/Equity Ratio
- 3.3%
Genomtec S.A. Competitors
Snowflake Analysis
About GMT
- Founded
- 2008
- Employees
- 26
- CEO
- WebsiteView website
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was incorporated in 2008 and is based in Wroclaw, Poland.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Polish Market Performance
- 7 Days: 0.2%
- 3 Months: 0.4%
- 1 Year: 24.7%
- Year to Date: 27.1%
Over the last 7 days, the market has remained flat, although notably the Materials sector gained 8.2% in that time. As for the longer term, the market has risen 25% in the past 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›